Morgan Stanley raised the firm’s price target on Medtronic (MDT) to $117 from $107 and keeps an Overweight rating on the shares. The firm updated its model following Q2 results, incorporating the latest financials and making modest changes tot its projections in light of business performance and guidance. The price target assumes Medtronic can trade at a slight premium to comps on more sustained operational execution/mid-single digit+ organic growth, the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MDT:
- Medtronic’s Strong Financial Performance and Growth Potential Justifies Buy Rating
- Medtronic price target raised to $115 from $100 at BofA
- Medtronic price target raised to $117 from $112 at Citi
- Medtronic’s Mixed Performance: Hold Rating Amid Revenue Growth and Margin Concerns
- Early notable gainers among liquid option names on November 18th